CAMP4, preparing for IPO, announces partnership with BioMarin
Regulatory RNA startup CAMP4 Therapeutics has inked another collaboration deal as it prepares for an initial public offering. The Cambridge, MA-based startup has lined up a pact with BioMarin to create...
View ArticleGritstone bio’s stock dips after it shares more data from failed Phase 2...
Months after announcing the failure of a mid-stage trial for its personalized neoantigen vaccine in cancer, Gritstone bio reported more data that it plans to take to regulators. In the Phase 2 trial,...
View ArticleTargeting Novartis' Scemblix, Enliven lays out case for leukemia drug in...
Enliven Therapeutics released new Phase 1 data for its chronic myeloid leukemia program (CML) it hopes can eventually compete with Novartis’ Scemblix. The experimental therapy, called ELVN-001, was...
View ArticleBiohaven aims to raise $250M; Activist investor's stake in Galapagos exceeds 10%
Plus, news about IN8bio, Sanofi, Vicore Pharma, Cartherics, Zephyrm Bioscience, Tharimmune and Intract Pharma: Biohaven’s $250M offering: The move comes after Biohaven announced Monday that it started...
View ArticleJ&J and Bayer to lay off almost 300 staffers in New Jersey
Two pharma giants are cutting staff in New Jersey, with Johnson & Johnson and Bayer making new layoffs between now and the end of December. Johnson and Johnson plans to cut 231 employees, according...
View ArticleJudge keeps Amgen's $10.7B tax liability suit alive
A New York federal judge has denied Amgen’s motion to dismiss a class action lawsuit alleging the company misled investors about a potential $10.7 billion tax liability. Plaintiffs, led by a Detroit...
View ArticleSenators question FDA and FTC over patent and PBM reforms
Senators may be back in their districts gearing up for next month’s elections, but that isn’t stopping them from questioning both the FDA and Federal Trade Commission on matters related to patent and...
View ArticleGSK’s ViiV stops development of Phase 2 HIV antiviral
GSK’s ViiV Healthcare has suspended development of a Phase 2-stage HIV antiviral named VH3739937, a GSK spokesperson confirmed to Endpoints News on Tuesday. The halt was prompted by “preliminary...
View ArticleLoQus23 bags $43M in Series A to move Huntington's drug into first human study
LoQus23 Therapeutics has secured £35 million ($43 million) in a Series A fundraise led by Forbion and backed by the venture arm of Novartis to help advance its lead Huntington’s disease program into...
View ArticleTriveni to take experimental eczema drug to the clinic, backed by new $115M...
On Wednesday, Triveni Bio became the latest immunology and inflammation startup this year to announce a $100 million-plus financing round. Money has come thick and fast to I&I companies this year,...
View ArticleClik here to view.
Exclusive: After discovering antibiotics with AI, a 31-year-old first-time...
Jim Collins, the famed MIT professor and a godfather of the synthetic biology field, describes Felix Wong as one of the most talented researchers to come out of his lab in recent years. Wong, 31, is...
View ArticleLilly invests $4.5B in new Indiana site to bring clinical manufacturing in-house
Eli Lilly is injecting $4.5 billion into a new manufacturing and drug development factory near its hometown of Indianapolis, in a move aimed at bringing clinical manufacturing in-house and speeding up...
View ArticleClik here to view.
Exclusive: Medicare navigation startup Connie Health is buying a Redesign...
Connie Health, a startup that matches seniors to Medicare plans, bought Redesign Health-backed competitor Keen Insurance Services as insurers step away from selling Medicare plans, driving seniors to...
View ArticleAI company Atomwise's founding CEO exits, casting doubt over startup
Atomwise’s founding CEO Abraham Heifets has left the company after a dozen years, Endpoints News has learned, in the latest challenge for one of the first AI-focused biotech startups. Heifets’ exit was...
View ArticleFrazier adds $630M to public fund to 'take advantage of market volatility'
Frazier Life Sciences has added more than $630 million to its evergreen public fund, the firm said Wednesday. The long-only fund, which is based in Palo Alto, CA, has been marketed to investors as a...
View ArticleWave’s new capital extends cash runway into 2027, CEO says
Wave Life Sciences brought in $230 million through an upsized public offering, extending its cash runway into 2027 as a handful of key programs advance. “It lets everybody breathe,” CEO Paul Bolno said...
View ArticleClik here to view.
Teladoc COO resigns amid executive shuffle
Teladoc’s chief operating officer has resigned due to an executive reshuffle, a few months after the company named a new CEO. Michael Waters COO Michael Waters’ resignation was related to “a change in...
View ArticleA blow to Humana’s Medicare Advantage quality ratings could tank its revenue...
After an already brutal year for its Medicare Advantage business, major health insurer Humana said it’s taken a hit to its health plan quality ratings that threatens to wipe away billions in revenue....
View ArticleJ&J budgets over $2B for new North Carolina biologics facility
Johnson & Johnson is earmarking over $2 billion to build a new biologics manufacturing facility in Wilson, NC, for a variety of therapies for oncology, immunology and neuroscience. Construction of...
View ArticleEMA looks to make its drug approval processes more efficient
The European Medicines Agency is looking to speed up its drug review timelines, following a recent report showing how applications can see long delays. Beginning in 2023, the EMA began monitoring every...
View Article